- Home
- LCTX vs PBYI Comparison
LCTX vs PBYI Comparison
Compare LCTX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- PBYI
- Stock Information
- Founded
- LCTX 1990
- PBYI 2010
- Country
- LCTX United States
- PBYI United States
- Employees
- LCTX N/A
- PBYI N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- PBYI Health Care
- Exchange
- LCTX Nasdaq
- PBYI Nasdaq
- Market Cap
- LCTX 274.0M
- PBYI 171.7M
- IPO Year
- LCTX N/A
- PBYI N/A
- Fundamental
- Price
- LCTX $1.55
- PBYI $4.52
- Analyst Decision
- LCTX Strong Buy
- PBYI Strong Buy
- Analyst Count
- LCTX 4
- PBYI 1
- Target Price
- LCTX $4.25
- PBYI $7.00
- AVG Volume (30 Days)
- LCTX 1.3M
- PBYI 525.6K
- Earning Date
- LCTX 11-13-2025
- PBYI 11-06-2025
- Dividend Yield
- LCTX N/A
- PBYI N/A
- EPS Growth
- LCTX N/A
- PBYI 434.29
- EPS
- LCTX N/A
- PBYI 0.97
- Revenue
- LCTX $10,914,000.00
- PBYI $238,062,000.00
- Revenue This Year
- LCTX N/A
- PBYI N/A
- Revenue Next Year
- LCTX $176.00
- PBYI N/A
- P/E Ratio
- LCTX N/A
- PBYI $4.64
- Revenue Growth
- LCTX 76.43
- PBYI 8.63
- 52 Week Low
- LCTX $0.37
- PBYI $2.32
- 52 Week High
- LCTX $1.62
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- LCTX 76.02
- PBYI 47.80
- Support Level
- LCTX $1.20
- PBYI $4.30
- Resistance Level
- LCTX $1.42
- PBYI $4.72
- Average True Range (ATR)
- LCTX 0.08
- PBYI 0.26
- MACD
- LCTX 0.02
- PBYI -0.10
- Stochastic Oscillator
- LCTX 85.26
- PBYI 19.30
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.